Free Trial
NASDAQ:KALV

KalVista Pharmaceuticals Q4 2025 Earnings Report

KalVista Pharmaceuticals logo
$14.29 +0.83 (+6.17%)
Closing price 04:00 PM Eastern
Extended Trading
$14.38 +0.09 (+0.63%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KalVista Pharmaceuticals EPS Results

Actual EPS
-$3.69
Consensus EPS
-$0.83
Beat/Miss
Missed by -$2.86
One Year Ago EPS
-$1.07

KalVista Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.20 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

KalVista Pharmaceuticals Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 10, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

KalVista Pharmaceuticals' Q1 2026 earnings is scheduled for Thursday, September 4, 2025, with a conference call scheduled on Tuesday, September 9, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

KalVista Pharmaceuticals Earnings Headlines

Did you spot this in the Oval Office last week?
When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to President Trump. But many viewers missed an even more important moment in that 30-second clip. One that unmistakably singled out what Futurist Eric Fry calls "possibly the best AI investment anyone could make right now." Eric believes this little-known partner to Apple could go crazy over the next 12-24 months, potentially leaving well-known AI stocks like Nvidia, Microsoft and Google in the dust.tc pixel
See More KalVista Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like KalVista Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KalVista Pharmaceuticals and other key companies, straight to your email.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals (NASDAQ:KALV), a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

View KalVista Pharmaceuticals Profile

More Earnings Resources from MarketBeat